TORONTO, Nov. 2, 2016 /CNW/ - Jason Flowerday, Chief Executive Officer, 3D Signatures Inc. (DXD), joined Eric Loree, Team Manager, Listed Issuer Services, TSX Venture Exchange to open the market. 3D Signatures Inc. is a personalized medicine company with proprietary software that can measure the stage of disease, rate of progression, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to customize treatment for patients. 3D Signatures Inc. commenced trading on TSX Venture Exchange on September 13, 2016.

SOURCE TMX Group Limited

Image with caption: "Jason Flowerday, Chief Executive Officer, 3D Signatures Inc. (DXD), joined Eric Loree, Team Manager, Listed Issuer Services, TSX Venture Exchange to open the market. 3D Signatures Inc. is a personalized medicine company with proprietary software that can measure the stage of disease, rate of progression, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to customize treatment for patients. 3D Signatures Inc. commenced trading on TSX Venture Exchange on September 13, 2016. (CNW Group/TMX Group Limited)". Image available at: http://photos.newswire.ca/images/download/20161102_C7237_PHOTO_EN_809966.jpg